A-395

Research use only, not for human use.

A-395 (A395) is a potent, selective, and cellularly active PRC2 subunit EED inhibitor with Kd of 1.5 nM.

A-395 (A395) is a potent, selective, and cellularly active PRC2 subunit EED inhibitor with Kd of 1.5 nM; potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with IC50 of 18 nM, and inhibits PRC2 at 1 and 50 uM, shows no activity against any of the other protein lysine methyltransferases, arginine methyltransferases, or DNA methyltransferases; inhibits both H3K27me2 and H3K27me3 with IC50 of 390 nM and 90 nM, respectively; exhibits potent antitumor efficacy in vivo.

The embryonic ectoderm development (EED) protein is an essential subunit of Polycomb repressive complex 2 (PRC2). A-395 antagonizes of the H3K27me3 binding functions of EED. A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2. A-395 is capable of competing for H3K27me3 peptide binding to EED, with an IC50 of 7 nM. A-395, but not the close chemical analog A-395N, modulates activity of PRC2 in cells by potently reducing the H3K27 methyl mark in a highly selective manner. A-395 treatment inhibits both H3K27me2 and H3K27me3, with IC50 values of 390 nM and 90 nM, respectively. Furthermore, A-395 treatment results in growth inhibition of human tumor cell lines sensitive to SAM-competitive EZH2 inhibitors.

The embryonic ectoderm development (EED) protein is an essential subunit of Polycomb repressive complex 2 (PRC2). A-395 antagonizes of the H3K27me3 binding functions of EED. A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2. A-395 is capable of competing for H3K27me3 peptide binding to EED, with an IC50 of 7 nM. A-395, but not the close chemical analog A-395N, modulates activity of PRC2 in cells by potently reducing the H3K27 methyl mark in a highly selective manner. A-395 treatment inhibits both H3K27me2 and H3K27me3, with IC50 values of 390 nM and 90 nM, respectively. Furthermore, A-395 treatment results in growth inhibition of human tumor cell lines sensitive to SAM-competitive EZH2 inhibitors.

A395

Chromatin/Epigenetic

HMTase

HMTase

Cancer

——

2089148-72-9

442.62

C24H34N4O2S

>98% (HPLC)

DMSO : 100 mg/mL 205.49 mM

CN(C)C1CN(CC1C2=CC=C(C=C2)N3CCN(CC3)S(=O)(=O)C)C4CCC5=C4C(=CC=C5)F

(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine

(-20℃)

With Ice Pack

≥ 2 years